Following on from information provided to NICE by the company in July 2022, the appraisal of Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Decision Selected
Process TA
ID number 3751

Timeline

Key events during the development of the guidance:

Date Update
25 July 2023 Discontinued. Following on from information provided to NICE by the company in July 2022, the appraisal of Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
18 July 2022 Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
16 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
29 January 2020 In progress. Topic is in progress

For further information on our processes and methods, please see our CHTE processes and methods manual